Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
AssigneeAmylin Pharmaceuticals, Inc.
InventorsThomas R. Coolidge, Mario R.W. Ehlers
Life of this patent
Estimating the term…
Abstract
Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagon-like peptide-1. The invention relates to both the method and compositions for such treatment.
Claims23
A method for amelioration of organ tissue injury caused by reperfusion of blood flow following a period of ischemia, which comprises:
- administering to an individual in need of such treatment an effective amount of a composition which includes a compound which binds to a receptor for glucagon-like peptide-1, in a pharmaceutical carrier.
The method of metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue, said method comprising:
- administering to an individual in need of such treatment an effective amount of a composition comprising GLP-1 in a pharmaceutical carrier.
A composition for use in metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue, comprising:
- an effective amount of GLP-1 in combination with a pharmaceutically effective carrier.
Dependencies are inferred from the claim text.